Algernon receives approval to conduct DMT study in the Netherlands

Mugglehead
By Rowan DunneSep 12, 2022, 9:28 pm228 pts
A Vancouver company will soon be dosing patients in a new clinical study aimed at benefitting people who have suffered the negative neurological impact of strokes. On Monday, Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) announced that it had received approval to conduct a phase 1…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Silk Road Drug Market Operator Pardoned By Trump Calls For More Prisoners To Be Freed, As Democrats Criticize His Clemency 70

Pennsylvania Governor Holds Tight to Cannabis Legalization in Budget Negotiations 65

Canadian Cannabis Sales Bounced Again 63

States attempt to quell hemp drink boom 2

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.